{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:36:40Z","timestamp":1747183000913,"version":"3.40.5"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pemetrexed was approved by United States Food and Drug Administration (US FDA) in combination with platinum for the treatment of advanced nonsquamous non\u2013small cell lung carcinoma (NSCLC) and malignant mesothelioma. Bevacizumab and pembrolizumab can be added to chemotherapy for patients with nonsquamous NSCLC with benefits but there has not been any dedicated head\u2010to\u2010head comparison between pembrolizumab\u2010pemetrexed\u2010platinum (PAC) and bevacizumab\u2010pemetrexed\u2010platinum (BAC) on their efficacy and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective single\u2010center cohort study conducted in Queen Mary Hospital in Hong Kong. The study included 451 patients with advanced stage nonsquamous NSCLC that received first\u2010line pemetrexed and platinum with or without bevacizumab or pembrolizumab. Patients who received pemetrexed\u2010platinum (AC) were compared with those who received PAC and BAC. The primary endpoint was the progression\u2010free survival (PFS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median PFS for patients that received PAC was significantly longer than those who received BAC and AC (9\u00a0months vs. 6.8\u00a0months vs. 4.8 months, <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.05 among all three groups), with OR of 0.578 (95% CI, 0.343\u20130.976; <jats:italic>p<\/jats:italic>\u00a0=\u00a00.040) and 0.430 (95% CI, 0.273\u20130.675; <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001) when compared to BAC and AC, respectively. Patients who received PAC also had a higher disease control rate and higher likelihood to receive continuation maintenance therapy than those on AC. There is no statistically significant difference in the grade 3 to 4 toxicity among the three treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although both regimens are superior to pemetrexed\u2010platinum alone, data from\u00a0this retrospective single center study suggested\u00a0a\u00a0better PFS in\u00a0 advanced stage nonsquamous NSCLC patient treated with first\u2010line\u00a0pembrolizumab\u2010pemetrexed\u2010platinum\u00a0than bevacizumab\u2010pemetrexed\u2010platinum without an obvious increase in significant toxicity.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.13658","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T02:36:06Z","timestamp":1650508566000},"page":"87-95","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non\u2013small cell carcinoma"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5611-1637","authenticated-orcid":false,"given":"Wang Chun","family":"Kwok","sequence":"first","affiliation":[{"name":"Department of Medicine Queen Mary Hospital  Pokfulam, Hong Kong Special Administrative Region China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tan Fong","family":"Cheong","sequence":"additional","affiliation":[{"name":"Department of Pneumology Centro Hospitalar Conde De Sao Januario  Estrada do Visconde de S Januario Macau SAR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka Yan","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Medicine Queen Mary Hospital  Pokfulam, Hong Kong Special Administrative Region China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James Chung Man","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Medicine Queen Mary Hospital  Pokfulam, Hong Kong Special Administrative Region China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Chi Leung","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Medicine Queen Mary Hospital  Pokfulam, Hong Kong Special Administrative Region China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Sau Man","family":"Ip","sequence":"additional","affiliation":[{"name":"Department of Medicine Queen Mary Hospital  Pokfulam, Hong Kong Special Administrative Region China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence Chi Chun","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Medicine Queen Mary Hospital  Pokfulam, Hong Kong Special Administrative Region China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.163"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.9887"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.JTO.0000268672.57002.69"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0232"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70063-3"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1547273"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.05.013"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-018-0327-3"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000207"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2020.1778179"},{"issue":"2","key":"e_1_2_7_12_1","article-title":"First\u2010line carboplatin plus pemetrexed with pemetrexed maintenance in HIV\u2010positive patients with advanced non\u2010squamous non\u2010small cell lung cancer: The phase II IFCT\u20101001 CHIVA trial","volume":"56","author":"Lavole A","year":"2020","journal-title":"Eur Respir J"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2018.09.003"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2018.324"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00884-2018"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.9626"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu098"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5146-3"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds590"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30498-3"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.004"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.08.019"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.12.015"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136"},{"issue":"3","key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","article-title":"Patient\u2010reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non\u2010squamous non\u2010small\u2010cell lung cancer (KEYNOTE\u2010189): A multicentre, double\u2010blind, randomised, placebo\u2010controlled, phase 3 trial","volume":"21","author":"Garassino MC","year":"2020","journal-title":"Lancet Oncol"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002208"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2020.1701439"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32368"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.11952"},{"key":"e_1_2_7_32_1","first-page":"JCO2100174","article-title":"Five\u2010Year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2010small\u2010cell lung cancer with pd\u2010l1 tumor proportion score >\/= 50","author":"Reck M","year":"2021","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30641-0"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.03.020"},{"key":"e_1_2_7_35_1","first-page":"CD013257","article-title":"Single or combined immune checkpoint inhibitors compared to first\u2010line platinum\u2010based chemotherapy with or without bevacizumab for people with advanced non\u2010small cell lung cancer","volume":"12","author":"Ferrara R","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_36_1","first-page":"JCO2003579","article-title":"Pembrolizumab plus ipilimumab or placebo for metastatic non\u2010small\u2010cell lung cancer with pd\u2010l1 tumor proportion score >\/= 50%: Randomized, double\u2010blind phase III KEYNOTE\u2010598 Study","author":"Boyer M","year":"2021","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123648"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13658","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13658","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T23:15:03Z","timestamp":1692573303000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1111\/ajco.13658"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13658","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"type":"print","value":"1743-7555"},{"type":"electronic","value":"1743-7563"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"assertion":[{"value":"2021-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}